

ASX ANNOUNCEMENT

5 July 2021

Clarification Announcement

Respiri Limited (ASX: RSH) (**Respiri**) refers to the announcement titled "Pharmacy Network to Commence Sales of wheezo" released on the ASX Market Announcements Platform on 23 June 2021.

Respiri wishes to clarify that the commencement of sales of wheezo™ across 570+ pharmacies within the Sigma Healthcare network Australia-wide should be understood within the context of the Exclusive Sales/Marketing, Distribution & Logistics Agreement with Cipla Limited signed in July 2020.

While Respiri's arrangement with Sigma will enable wheezo units to be sold in pharmacies across the Sigma Healthcare network, those wheezo units will be supplied to Sigma by Cipla under Cipla's existing distribution agreement with Respiri referred to above. For clarity, Respiri will not be supplying units of wheezo directly to Sigma, as Respiri has no direct supply agreement with Sigma.

Although Respiri has not agreed to any minimum supply figures with Sigma, Respiri confirms that the arrangement with Sigma will open up new opportunities for Respiri to have its wheezo device on retail shelves.

While wheezo is not yet available in pharmacies within the Sigma Healthcare network, an initial purchase order from Sigma relating to the preliminary delivery of wheezo units to its distribution centre was received from Respiri in June 2021. Respiri currently expects that pharmacies within the Sigma Healthcare network will have units of wheezo in their stores in July 2021.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

wheezo® is a registered trademark of Respiri Limited.

This ASX announcement dated 5 July 2021 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.